2,527products in the catalogue
2,367EU-authorised medicines (EMA)
160FDA approvals
5 yrsforecast horizon, 2027–2031
Free report
The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Two ways to buy
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
€1,250 per product
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
€4,950 5 products
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
from €4,500
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
What is in every report
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Catalogue
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Dafiro HCT amlodipine besilate;valsartan;hydrochlorothiazide | Novartis Europharm Limited | Hypertension | 🇪🇺 EU 2009-11-03 | Order → |
| Repaglinide Krka repaglinide Generic | KRKA tovarna zdravil d.d. Novo mesto | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2009-11-03 | Order → |
| Irbesartan Teva irbesartan Generic | Teva B.V. | Hypertension | 🇪🇺 EU 2009-10-30 | Order → |
| Eporatio epoetin theta | Ratiopharm GmbH | Kidney Failure, Chronic; Anemia; Cancer | 🇪🇺 EU 2009-10-29 | Order → |
| Biopoin epoetin theta | Teva GmbH | Kidney Failure, Chronic; Anemia; Cancer | 🇪🇺 EU 2009-10-23 | Order → |
| Ilaris canakinumab | Novartis Europharm Limited | Cryopyrin-Associated Periodic Syndromes; Arthritis, Juvenile Rheumatoid; Arthritis, Gouty | 🇪🇺 EU 2009-10-23 | Order → |
| Lamivudine Teva lamivudine Generic | Teva B.V. | Hepatitis B, Chronic | 🇪🇺 EU 2009-10-23 | Order → |
| Rilonacept Regeneron (previously Arcalyst) rilonacept Exceptional circumstances | Regeneron UK Limited | Cryopyrin-Associated Periodic Syndromes | 🇪🇺 EU 2009-10-23 | Order → |
| Foclivia pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Exceptional circumstances | Seqirus S.r.l. | Influenza, Human; Immunization; Disease Outbreaks | 🇪🇺 EU 2009-10-18 | Order → |
| Clopidogrel Viatris (previously Clopidogrel Taw Pharma) clopidogrel Generic | Viatris Limited | Peripheral Vascular Diseases; Stroke; Myocardial Infarction | 🇪🇺 EU 2009-10-16 | Order → |
| Pandemic Influenza Vaccine H5N1 Baxter AG pandemic influenza vaccine (H5N1) (whole virion, inactivated, prepared in cell culture) Exceptional circumstances | Resilience Biomanufacturing Ireland Limited | Influenza, Human; Immunization; Disease Outbreaks | 🇪🇺 EU 2009-10-16 | Order → |
| Vantavo (previously Alendronate sodium and colecalciferol, MSD) alendronic acid;colecalciferol | Organon N.V. | Osteoporosis, Postmenopausal | 🇪🇺 EU 2009-10-16 | Order → |
| Exforge HCT amlodipine besilate;valsartan;hydrochlorothiazide | Novartis Europharm Limited | Hypertension | 🇪🇺 EU 2009-10-15 | Order → |
| Imprida HCT amlodipine;valsartan;hydrochlorothiazide | Novartis Europharm Ltd. | Hypertension | 🇪🇺 EU 2009-10-15 | Order → |
| Resolor prucalopride | Takeda Pharmaceuticals International AG Ireland | Constipation | 🇪🇺 EU 2009-10-14 | Order → |
| Enyglid repaglinide Generic | KRKA tovarna zdravil d.d. Novo mesto | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2009-10-13 | Order → |
| Adjupanrix (previously Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals) pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) Exceptional circumstances | GlaxoSmithKline Biologicals S.A. | Influenza, Human; Immunization; Disease Outbreaks | 🇪🇺 EU 2009-10-10 | Order → |
| ChondroCelect characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins ATMP | TiGenix N.V. | Cartilage Diseases | 🇪🇺 EU 2009-10-05 | Order → |
| Cimzia certolizumab pegol | UCB Pharma | Arthritis, Rheumatoid | 🇪🇺 EU 2009-10-01 | Order → |
| Simponi golimumab | Janssen Cilag International NV | Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Arthritis, Rheumatoid | 🇪🇺 EU 2009-10-01 | Order → |
Order
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.